In turn, according to Bratek-Gerej et al. (2021), administration of KYNA intraperitoneally (50, 150, 300 mg/kg) to a rat model of neonatal hypoxia-ischemia resulted in a reduction in ROS level and activity of antioxidant enzymes (SOD, glutathione peroxidase and catalase) and a partial restoration of GSH content in the brain. The gene discussed is CAT; the disease is ischemia.